NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.00
  • Forecasted Upside: 447.95 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.73
▼ -0.05 (-6.41%)

This chart shows the closing price for SPPI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Spectrum Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SPPI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SPPI

Analyst Price Target is $4.00
▲ +447.95% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Spectrum Pharmaceuticals in the last 3 months. The average price target is $4.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 447.95% upside from the last price of $0.73.

This chart shows the closing price for SPPI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Spectrum Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/19/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/17/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/18/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2022JMP SecuritiesReiterated RatingBuy$4.00Low
4/1/2022Cantor FitzgeraldReiterated RatingNeutralHigh
3/21/2022JMP SecuritiesReiterated RatingBuy$4.00High
3/21/2022B. RileyLower Price TargetBuy$6.00 ➝ $4.00High
3/8/2022JMP SecuritiesReiterated RatingBuy$4.00Low
11/12/2021B. RileyReiterated RatingBuyHigh
9/20/2021JMP SecuritiesReiterated RatingBuy$4.00High
8/18/2021B. RileyLower Price TargetBuy$8.00 ➝ $6.00High
4/12/2021B. RileyReiterated RatingBuy$8.00High
10/26/2020HC WainwrightLower Price TargetBuy$13.00 ➝ $12.00High
9/17/2020JMP SecuritiesInitiated CoverageOutperform$12.00High
8/11/2020HC WainwrightReiterated RatingBuy$13.00High
8/3/2020HC WainwrightBoost Price TargetBuy$11.00 ➝ $13.00Medium
7/28/2020Cantor FitzgeraldBoost Price TargetPositive ➝ Neutral$4.00 ➝ $7.00High
7/2/2020B. RileyReiterated RatingBuy$8.00N/A
6/22/2020B. RileyReiterated RatingBuy$8.00High
3/2/2020B. RileyLower Price TargetBuy$11.00 ➝ $8.00Medium
12/27/2019B. RileyLower Price TargetBuy$18.00 ➝ $11.00High
12/26/2019GuggenheimDowngradeBuy ➝ NeutralN/A
12/26/2019HC WainwrightInitiated CoverageBuy$41.00 ➝ $11.00N/A
12/26/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Neutral$17.00 ➝ $4.00N/A
11/27/2019B. RileyInitiated CoverageBuy$18.00Medium
10/25/2019HC WainwrightReiterated RatingBuyHigh
8/23/2019B. RileySet Price TargetBuy$18.00High
7/11/2019B. RileyInitiated CoverageBuy ➝ Buy$18.00Medium
5/13/2019GuggenheimInitiated CoverageBuy$19.00High
3/15/2019Jefferies Financial GroupReiterated RatingBuy ➝ Buy$21.00High
2/7/2019Cantor FitzgeraldInitiated CoverageOverweight$19.00High
1/10/2019HC WainwrightReiterated RatingBuy$40.00High
12/20/2018B. RileyLower Price TargetBuy$21.00High
11/12/2018B. RileyLower Price TargetBuy ➝ Buy$35.00 ➝ $29.00High
9/6/2018HC WainwrightBoost Price TargetBuy$40.00High
8/31/2018B. RileyBoost Price TargetBuy ➝ Buy$26.00 ➝ $35.00Medium
6/29/2018HC WainwrightReiterated RatingBuy$33.00Low
2/5/2018HC WainwrightBoost Price TargetPositive ➝ Buy$33.00High
12/18/2017HC WainwrightReiterated RatingBuy$29.00High
12/18/2017B. RileyInitiated CoverageBuy ➝ Buy$26.00High
11/3/2017HC WainwrightReiterated RatingBuyN/A
10/23/2017GuggenheimInitiated CoverageBuy$32.00N/A
10/20/2017Jefferies Financial GroupBoost Price TargetBuy$25.00N/A
10/18/2017HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $29.00N/A
10/9/2017Jefferies Financial GroupBoost Price TargetBuy$13.00 ➝ $18.00N/A
9/25/2017Jefferies Financial GroupBoost Price TargetBuy$9.00 ➝ $13.00High
9/14/2017HC WainwrightReiterated RatingBuy$14.00Low
8/25/2017Jefferies Financial GroupSet Price TargetBuy$9.00Medium
8/16/2017HC WainwrightReiterated RatingBuy ➝ Buy$14.00Low
6/8/2017Jefferies Financial GroupSet Price TargetBuy$9.00Low
(Data available from 5/19/2017 forward)

News Sentiment Rating

0.82 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
10/21/2021
  • 4 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
11/20/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/20/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/19/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
2/18/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/20/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/19/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/19/2022

Current Sentiment

  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Spectrum Pharmaceuticals logo
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Henderson, Nevada.
Read More

Today's Range

Now: $0.73
Low: $0.73
High: $0.81

50 Day Range

MA: $1.00
Low: $0.71
High: $1.40

52 Week Range

Now: $0.73
Low: $0.60
High: $4.54

Volume

2,062,383 shs

Average Volume

3,882,899 shs

Market Capitalization

$131.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Spectrum Pharmaceuticals?

The following equities research analysts have issued reports on Spectrum Pharmaceuticals in the last twelve months: B. Riley, Cantor Fitzgerald, JMP Securities, StockNews.com, and Zacks Investment Research.
View the latest analyst ratings for SPPI.

What is the current price target for Spectrum Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Spectrum Pharmaceuticals in the last year. Their average twelve-month price target is $4.00, suggesting a possible upside of 447.9%.
View the latest price targets for SPPI.

What is the current consensus analyst rating for Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SPPI will outperform the market and that investors should add to their positions of Spectrum Pharmaceuticals.
View the latest ratings for SPPI.

How do I contact Spectrum Pharmaceuticals' investor relations team?

Spectrum Pharmaceuticals' physical mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company's listed phone number is (702) 835-6300 and its investor relations email address is [email protected] The official website for Spectrum Pharmaceuticals is www.sppirx.com. Learn More about contacing Spectrum Pharmaceuticals investor relations.